2seventy bio Inc (NASDAQ:TSVT) currently has a daily average trading volume of 1.28M but it saw 1199806 shares traded in last market. With a market cap of 265.61M USD, the company’s current market price of $4.99 remained unchanged while comparing to the previous closing price of $4.99. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.30 and as low as $2.29. In the recent trading on the day, stock has struck highest price mark of $4.98 while lowest mark touched by it was $5.0.
Taking a look at 20-day trading activity of 2seventy bio Inc (TSVT) gives us an average price of $4.97, while its current price level is -5.85% below from 52-week high level whereas it is 117.90% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $4.31 while that of 200 days or SMA-200 reads an average of $4.05. A closer look into the stock’s movement over the week reveals that its volatility is standing at 0.24% during that period while stretching the period over a month that increases to 0.50%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 76.05 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Goldman which downgraded the stock as “Sell” in its note to investors issued on June 06, 2024, recommending a price target of between $5 and $2 for it. Leerink Partners upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on January 31, 2024 while assigning a price target range of $5-$18.
Year-to-date it is 69.73% up and over the past year, the stock is showing an upside performance of 17.27%.
The company is expected to be releasing its next quarterly report on 2025-Mar-24, for which analysts forecasted an EPS of -0.1 while estimate for next year EPS is -0.16. In next quarter, company is expected to be making quarterly sales of $13.43M as analysts are expecting the sales for current fiscal year at $68.47M and seeing the company making $75.12M in sales next year. Moreover, analysts are in estimates of $13.96M for current-quarter revenue.
Currently, 2seventy bio Inc’s total number of outstanding shares is 51.59M with 6.44% of that held by the insiders while 83.60% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -13.07% and return on equity (ROE) at -24.56%. Stock’s beta reads 1.05. Stock has a price to book (P/B) ratio of 1.22 while price to sale or P/S ratio amounts to 7.02. Its return on asset (ROA) is -10.96% on average.
